Aikening® is the commercial brand name of Albuvirtide for Injection, a long‑acting HIV fusion inhibitor peptide drug. It binds to the gp41 subunit of HIV‑1 envelope glycoprotein, blocks viral membrane fusion with host cell membrane and prevents HIV entry into human cells.
Main Indications
In combination with other antiretroviral drugs, for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults.
Clinical Research
Phase III clinical trial demonstrated that once‑weekly albuvirtide combined with optimized background regimen achieved significant HIV‑1 RNA viral load reduction in treatment‑experienced HIV‑1 infected adults;
The study showed durable viral suppression and favorable tolerability profile;
Pharmacokinetic data confirmed its long half‑life supporting weekly subcutaneous administration.
Common Side Effects
Severe but important risks: Severe injection site reactions, hypersensitivity reactions, immune reconstitution inflammatory syndrome;
Common mild adverse reactions: Injection site pain, nodule and pruritus, diarrhea, nausea, fatigue, dizziness and elevated triglycerides.
Approval Status in China
Original drug Aikening® (Albuvirtide for Injection, specification:160mg per vial) was officially approved for marketing in China in 2018. It is currently a prescription long‑acting anti‑HIV peptide drug.
Buy Aikening (Albuvirtide for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
